ph 3 trial fails primary endpoint, page-10

From ann:

CEO Gary Phillips said "it seems likely that a clinically meaningful subgroup of Bronchitol patients can be identified to form the basis for discussions with regulatory authorities on approvable clinical trial designs."

So these clowns propose to find a subgroup of patients and do more trials.....am I interpreting this right?? And what do we all think the time frame for this will be??

Really, really annoyed. Too annoyed to even listen to this conference call. Can someone fill me in on what they say while I watch the share price plummet.